News | November 25, 2023
Laurus Labs acquires 87.59% stake in Laurus Bio Private
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
Eris Lifesciences enters into term loan agreement with Citi Bank
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
Subscribe To Our Newsletter & Stay Updated
